Larimar Therapeutics Inc (LRMR) — Cash Flow-to-Debt Ratio
Larimar Therapeutics Inc (LRMR) has a Cash Flow-to-Debt Ratio of -0.88x as of March 2026, meaning its operating cash flow of $-44.61 Million could theoretically repay -1% of its total liabilities ($50.48 Million) in one year. Explore LRMR strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Larimar Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Larimar Therapeutics Inc across 14 annual periods. Also explore Larimar Therapeutics Inc assets under control for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Larimar Therapeutics Inc (2012–2025)
Year-by-year debt coverage analysis for Larimar Therapeutics Inc. For market capitalisation and broader financial context, see Larimar Therapeutics Inc (LRMR) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.67x | $-113.20 Million | $67.76 Million | ▲ +32.9% |
| 2024 | -2.49x | $-70.76 Million | $28.41 Million | ▼ -5.8% |
| 2023 | -2.35x | $-33.46 Million | $14.21 Million | ▼ -32.4% |
| 2022 | -1.78x | $-27.57 Million | $15.50 Million | ▲ +39.8% |
| 2021 | -2.95x | $-42.10 Million | $14.25 Million | ▼ -5.0% |
| 2020 | -2.81x | $-42.20 Million | $14.99 Million | ▲ +26.9% |
| 2019 | -3.85x | $-22.70 Million | $5.89 Million | ▼ -113.1% |
| 2018 | -1.81x | $-51.49 Million | $28.49 Million | ▼ -12.6% |
| 2017 | -1.60x | $-43.78 Million | $27.29 Million | ▲ +69.5% |
| 2016 | -5.25x | $-51.98 Million | $9.89 Million | ▼ -76.4% |
| 2015 | -2.98x | $-59.55 Million | $20.00 Million | ▼ -37.9% |
| 2014 | -2.16x | $-28.24 Million | $13.08 Million | ▲ +58.0% |
| 2013 | -5.15x | $-15.00 Million | $2.92 Million | ▼ -11.0% |
| 2012 | -4.64x | $-13.59 Million | $2.93 Million | — |